Document is current
Any future updates will be listed below
-
Authors
Spagnolli, Giovanni https://orcid.org/0000-0002-0578-0558
Massignan, Tania
Astolfi, Andrea
Biggi, Silvia
Rigoli, Marta https://orcid.org/0000-0001-7448-1896
Brunelli, Paolo
Libergoli, Michela
Ianeselli, Alan
Orioli, Simone
Boldrini, Alberto https://orcid.org/0000-0002-8519-0709
Terruzzi, Luca https://orcid.org/0000-0003-2491-0415
Bonaldo, Valerio https://orcid.org/0000-0001-7420-4063
Maietta, Giulia
Lorenzo, Nuria L.
Fernandez, Leticia C.
Codeseira, Yaiza B.
Tosatto, Laura
Linsenmeier, Luise
Vignoli, Beatrice
Petris, Gianluca https://orcid.org/0000-0002-2420-6359
Gasparotto, Dino
Pennuto, Maria https://orcid.org/0000-0001-8634-0767
Guella, Graziano https://orcid.org/0000-0002-1799-0819
Canossa, Marco
Altmeppen, Hermann C. https://orcid.org/0000-0001-9439-6533
Lolli, Graziano
Biressi, Stefano https://orcid.org/0000-0001-8631-3419
Pastor, Manuel M.
Requena, Jesús R.
Mancini, Ines
Barreca, Maria L. https://orcid.org/0000-0003-3530-5042
Faccioli, Pietro
Biasini, Emiliano https://orcid.org/0000-0002-3927-6341
-
Funding
Funding for this research was provided by:
Fondazione Telethon (TCP14009)
- License Information
-
More Information
Article History
Received: 7 August 2020
Accepted: 9 December 2020
First Online: 12 January 2021
Competing interests
: The authors declare the following competing interests: G.S., G.L., L.M.B., P.F., and E.B. are co-founders and shareholders of Sibylla Biotech SRL. The company exploits the PPI-FIT technology for drug discovery in a wide variety of human pathologies, with the exception of prion diseases.
